Tumor uptake of the PSMA‐targeting 111In‐DTPA‐SCN‐antibody was significantly greater than that of 111In‐DTPA‐loaded liposomes (Figure 5c); this was partly attributed to the different blood clearance half‐lives of each carrier (Figure 5d). This evidence concerns the gene FOLH1 and neoplasm.